Literature DB >> 3956216

Use of constant-infusion verapamil for the treatment of postoperative supraventricular tachycardia.

T J Iberti, E Benjamin, T A Paluch, D R Gentili, G V Gabrielson.   

Abstract

The effects of constant-infusion verapamil were studied in ten postoperative ICU patients who developed supraventricular tachycardia (atrial fibrillation) with rapid ventricular response rates. A 5-mg iv bolus dose of verapamil was followed by a 5-mg/h infusion that continued for 8 h. Ventricular rates were significantly (p less than .005) reduced from a pretreatment mean of 156 +/- 14 (SD) to 104 +/- 9 beat/min on constant-infusion therapy. This therapy was well tolerated without observed side-effects. Moreover, constant-infusion verapamil might avoid the hypotension and wide range of ventricular rates frequently encountered with repeated bolus doses of verapamil.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3956216     DOI: 10.1097/00003246-198604000-00006

Source DB:  PubMed          Journal:  Crit Care Med        ISSN: 0090-3493            Impact factor:   7.598


  3 in total

Review 1.  Calcium-channel blockers and anaesthesia.

Authors:  P G Durand; J J Lehot; P Foëx
Journal:  Can J Anaesth       Date:  1991-01       Impact factor: 5.063

Review 2.  New-onset atrial fibrillation in adult critically ill patients: a scoping review.

Authors:  Mik Wetterslev; Nicolai Haase; Christian Hassager; Emilie P Belley-Cote; William F McIntyre; Youzhong An; Jiawei Shen; Alexandre Biasi Cavalcanti; Fernando G Zampieri; Helio Penna Guimaraes; Anders Granholm; Anders Perner; Morten Hylander Møller
Journal:  Intensive Care Med       Date:  2019-05-14       Impact factor: 17.440

3.  Landiolol hydrochloride for early postoperative tachycardia after transthoracic esophagectomy.

Authors:  Kazuhiko Mori; Kazuhiko Yamada; Takashi Fukuda; Takashi Mitsui; Takayuki Kitamura; Daisuke Yamaguchi; Jiro Ando; Ikuo Wada; Sachiyo Nomura; Nobuyuki Shimizu; Yasuyuki Seto
Journal:  Surg Today       Date:  2013-05-15       Impact factor: 2.549

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.